

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. For curative treatment options, early diagnosis is crucial. In this context, the present invention provides a new contrast agent, made of Gd-DTPA-loaded HSA-/PLGA-nanoparticles for magnetic resonance imaging (MRI) enabling the detection of small HCC which are undetectable with current methods and improving differentiation between HCC and benign lesions in the cirrhotic lever.
Further Information: PDF
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0
Contact
Dr. Otmar Schöller